Síguenos en:

Síguenos en Twitter Siguenos en Facebook Siguenos en Google+ Siguenos en por RSS

lunes, 28 de enero de 2013

Meningococemia: Sepsis meningocócica con purpura fulminante 


Aspectos generales de septicemia por meningococos: En República Dominicana no se habían notificado casos relevantes en el 2012 hasta el 24 de diciembre cuando se dio a conocer un caso relevante que aparecio procedente del pais de Chile en America del sur.




  •    Resumen



  • La meningococcemia puede matar más rápidamente que cualquier otra enfermedad infecciosa. 
  • N. meningitidis es la principal causa infecciosa de muerte infantil en los países desarrollados. 
  • La tasa de mortalidad sigue siendo alrededor de 10%, aunque en algunos centros especializados, se ha disminuido a menos del 5%. 
  • La detección precoz es fundamental para aplicar la terapia antibiótica y pronta atención de apoyo. 
  • El tratamiento debe instituirse rápidamente debido a shock irreversible y la muerte puede ocurrir en cuestión de horas desde la aparición de los síntomas. 
  • Manifestaciones cutáneas en la meningococemia pueden ser claves importantes para el diagnóstico. 
  • La afectación cutánea puede ser el aspecto más dramático de la enfermedad y es a menudo el primer signo de que lleva a la consideración clínica de meningococcemia.
                                                                                                                                                               




  •  Artículos relacionados

> Nuevos aspectos sobre la Coagulacion Intravascular Diseminada (CID)



  •  Referencias bibilográficas 


  • Jarva H, Ram S, Vogel U, Blom AM, Meri S. Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J Immunol. May 15 2005;174(10):6299-307.
  • Nkosi J, Thakrar A, Kumar K, Ahmadie R, Fang T, Lytwyn M, et al. Meningococcal serotype Y myopericarditis. Diagn Microbiol Infect Dis. Feb 2009;63(2):223-7. 
  • Horino T, Kato T, Sato F, Sakamoto M, Nakazawa Y, Yoshida M, et al. Meningococcemia without meningitis in Japan. Intern Med. 2008;47(17):1543-7. 
  • Pollard AJ, Nadel S, Ninis N, Faust SN, Levin M. Emergency management of meningococcal disease: eight years on. Arch Dis Child. Apr 2007;92(4):283-6.
  • Razminia M, Salem Y, Elbzour M, Teves D, Deshmukh H, Khosla S. Importance of early diagnosis and therapy of acute meningococcal myocarditis: a case report with review of literature. Am J Ther. May-Jun 2005;12(3):269-71.  
  • Pathan N, Faust SN, Levin M. Pathophysiology of meningococcal meningitis and septicaemia. Arch Dis Child. Jul 2003;88(7):601-7. 
  • Livorsi DJ, Stenehjem E, Stephens DS. Virulence factors of gram-negative bacteria in sepsis with a focus on Neisseria meningitidis. Contrib Microbiol. 2011;17:31-47.
  • Zughaier SM. Neisseria meningitidis capsular polysaccharides induce inflammatory responses via TLR2 and TLR4-MD-2. J Leukoc Biol. Mar 2011;89(3):469-80.
  • Plant L, Sundqvist J, Zughaier S, Lövkvist L, Stephens DS, Jonsson AB. Lipooligosaccharide structure contributes to multiple steps in the virulence of Neisseria meningitidis. Infect Immun. Feb 2006;74(2):1360-7.
  • Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. Aug 9 2001;345(6):408-16. 
  • Pathan N, Hemingway CA, Alizadeh AA, Stephens AC, Boldrick JC, Oragui EE, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet. Jan 17 2004;363(9404):203-9. 
  • Pathan N, Williams EJ, Oragui EE, Stephens AC, Levin M. Changes in the interleukin-6/soluble interleukin-6 receptor axis in meningococcal septic shock. Crit Care Med. Aug 2005;33(8):1839-44. 
  • El Bashir H, Laundy M, Booy R. Diagnosis and treatment of bacterial meningitis. Arch Dis Child. Jul 2003;88(7):615-20. 
  • MacLennan J, Kafatos G, Neal K, Andrews N, Cameron JC, Roberts R, et al. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis. Jun 2006;12(6):950-7.
  • Faber J, Henninger N, Finn A, Zenz W, Zepp F, Knuf M. A toll-like receptor 4 variant is associated with fatal outcome in children with invasive meningococcal disease. Acta Paediatr. Mar 2009;98(3):548-52. 
  • Jansen AG, Sanders EA, VAN DER Ende A, VAN Loon AM, Hoes AW, Hak E. Invasive pneumococcal and meningococcal disease: association with influenza virus and respiratory syncytial virus activity?. Epidemiol Infect. Nov 2008;136(11):1448-54. 
  • Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis. Jan 1 2008;46(1):1-13.
  • Cathie K, Levin M, Faust SN. Drug use in acute meningococcal disease. Arch Dis Child Educ Pract Ed. Oct 2008;93(5):151-8.
  • Tappero JW, Reporter R, Wenger JD, Ward BA, Reeves MW, Missbach TS, et al. Meningococcal disease in Los Angeles County, California, and among men in the county jails. N Engl J Med. Sep 19 1996;335(12):833-40. 
  • Brundage JF, Ryan MA, Feighner BH, Erdtmann FJ. Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964-1998. Clin Infect Dis. Dec 1 2002;35(11):1376-81.
  • Wilder-Smith A. W135 meningococcal carriage in association with the Hajj pilgrimage 2001: the Singapore experience. Int J Antimicrob Agents. Feb 2003;21(2):112-5.
  • Wilder-Smith A, Barkham TM, Earnest A, Paton NI. Acquisition of W135 meningococcal carriage in Hajj pilgrims and transmission to household contacts: prospective study. BMJ. Aug 17 2002;325(7360):365-6. 
  • Wilder-Smith A, Chow A, Goh KT. Emergence and disappearance of W135 meningococcal disease. Epidemiol Infect. Jul 2010;138(7):976-8.
  • Vyse A, Wolter JM, Chen J, Ng T, Soriano-Gabarro M. Meningococcal disease in Asia: an under-recognized public health burden. Epidemiol Infect. Apr 15 2011;1-19.
  • Davison KL, Ramsay ME. The epidemiology of acute meningitis in children in England and Wales. Arch Dis Child. Aug 2003;88(8):662-4. 
  • Health Protection Agency. Invasive meningococcal infections, England and Wales, laboratory reports: weeks 51-52/2007.
  • Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. Dec 2010;10(12):853-61. 
  • Moura AS, Pablos-Méndez A, Layton M, Weiss D. Epidemiology of meningococcal disease, New York City, 1989-2000. Emerg Infect Dis. Mar 2003;9(3):355-61.
  • Kaplan SL, Schutze GE, Leake JA, Barson WJ, Halasa NB, Byington CL, et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics. Oct 2006;118(4):e979-84.
  • Darton T, Guiver M, Naylor S, Jack DL, Kaczmarski EB, Borrow R, et al. Severity of meningococcal disease associated with genomic bacterial load. Clin Infect Dis. Mar 1 2009;48(5):587-94. 
  • Vienne P, Ducos-Galand M, Guiyoule A, Pires R, Giorgini D, Taha MK, et al. The role of particular strains of Neisseria meningitidis in meningococcal arthritis, pericarditis, and pneumonia. Clin Infect Dis. Dec 15 2003;37(12):1639-42.
  • Wong JS, Balakrishnan V. Neisseria meningitidis endogenous endophthalmitis: case report and literature review. J Pediatr Ophthalmol Strabismus. May-Jun 1999;36(3):145-52.  
  • Zeidan A, Tariq S, Faltas B, Urban M, McGrody K. A case of primary meningococcal pericarditis caused by Neisseria meningitidis serotype Y with rapid evolution into cardiac tamponade. J Gen Intern Med. Sep 2008;23(9):1532-5.  
  • Borg J, Christie D, Coen PG, Booy R, Viner RM. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics. Mar 2009;123(3):e502-9.
  • Buysse CM, Raat H, Hazelzet JA, Hulst JM, Cransberg K, Hop WC, et al. Long-term health status in childhood survivors of meningococcal septic shock. Arch Pediatr Adolesc Med. Nov 2008;162(11):1036-41.
  • Buysse CM, Oranje AP, Zuidema E, Hazelzet JA, Hop WC, Diepstraten AF, et al. Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock. Arch Dis Child. May 2009;94(5):381-6.
  • Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. Jun 30 2007;369(9580):2196-210.
  • Welch SB, Nadel S. Treatment of meningococcal infection. Arch Dis Child. Jul 2003;88(7):608-14. 
  • Feldman HA. Meningococcal infections. Adv Intern Med. 1972;18:117-40.
  • Parmentier L, Garzoni C, Antille C, Kaiser L, Ninet B, Borradori L. Value of a novel Neisseria meningitidis--specific polymerase chain reaction assay in skin biopsy specimens as a diagnostic tool in chronic meningococcemia. Arch Dermatol. Jun 2008;144(6):770-3. 
  • Periappuram M, Taylor MR, Keane CT. Rapid detection of meningococci from petechiae in acute meningococcal infection. J Infect. Nov 1995;31(3):201-3. 
  • Arend SM, Lavrijsen AP, Kuijken I, van der Plas RN, Kuijper EJ. Prospective controlled study of the diagnostic value of skin biopsy in patients with presumed meningococcal disease. Eur J Clin Microbiol Infect Dis. Oct 2006;25(10):643-9. 
  • Dolan Thomas J, Hatcher CP, Satterfield DA, Theodore MJ, Bach MC, Linscott KB, et al. sodC-based real-time PCR for detection of Neisseria meningitidis. PLoS One. May 5 2011;6(5):e19361. 
  • Guarner J, Greer PW, Whitney A, Shieh WJ, Fischer M, White EH, et al. Pathogenesis and diagnosis of human meningococcal disease using immunohistochemical and PCR assays. Am J Clin Pathol. Nov 2004;122(5):754-64. 
  • Fernández-Rodríguez A, Alcalá B, Alvarez-Lafuente R. Real-time polymerase chain reaction detection of Neisseria meningitidis in formalin-fixed tissues from sudden deaths. Diagn Microbiol Infect Dis. Apr 2008;60(4):339-46.  
  • Bryant PA, Li HY, Zaia A, Griffith J, Hogg G, Curtis N, et al. Prospective study of a real-time PCR that is highly sensitive, specific, and clinically useful for diagnosis of meningococcal disease in children. J Clin Microbiol. Jul 2004;42(7):2919-25.  
  • de Filippis I, do Nascimento CR, Clementino MB, Sereno AB, Rebelo C, Souza NN, et al. Rapid detection of Neisseria meningitidis in cerebrospinal fluid by one-step polymerase chain reaction of the nspA gene. Diagn Microbiol Infect Dis. Feb 2005;51(2):85-90. 
  • Lin HW, Yin JH, Lo JP, Wang YH, Lee SY, Lu JJ. Use of universal polymerase chain reaction assay and endonuclease digestion for rapid detection of Neisseria meningitides. J Microbiol Immunol Infect. Dec 2004;37(6):371-4. 
  • Richardson DC, Louie L, Louie M, Simor AE. Evaluation of a rapid PCR assay for diagnosis of meningococcal meningitis. J Clin Microbiol. Aug 2003;41(8):3851-3.
  • Health Protection Agency. Guidance for the public health management of meningococcal disease in the UK. 
  • [Guideline] Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics. Aug 2005;116(2):496-505.
  • [Guideline] Revised recommendations of the Advisory Committee on Immunization Practices to Vaccinate all Persons Aged 11-18 Years with Meningococcal Conjugate Vaccine. MMWR Morb Mortal Wkly Rep. Aug 10 2007;56(31):794-5. 
  • [Guideline] Scottish Intercollegiate Guidelines Network (SIGN). Management of invasive meningococcal disease in children and young people. A national clinical guideline. National Guidelines Clearinghouse. May 2008. 
  • Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. Jan 10 2008;358(2):111-24. 
  • Jaeschke R, Angus DC. Living with uncertainty in the intensive care unit: should patients with sepsis be treated with steroids?. JAMA. Jun 10 2009;301(22):2388-90. 
  • Tuncer AM, Gür I, Ertem U, Ece A, Türkmen S, Deniz B, et al. Once daily ceftriaxone for meningococcemia and meningococcal meningitis. Pediatr Infect Dis J. Oct 1988;7(10):711-3. 
  • Hart CA, Cuevas LE. Meningococcal disease in Africa. Ann Trop Med Parasitol. Oct 1997;91(7):777-85. 
  • Food and Drug Administration. Ceftriaxone (marketed as Rocephin) information. 2008:
  • Roche. Important clarification of prescribing information. Contraindications. http://www.rocheusa.com. Available at http://www.gene.com/gene/products/information/rocephin. Accessed June 28, 2012. 
  • Medicines and healthcare products regulatory agency. Ceftriaxone; incompatibility with calcium containing solutions. 2008: 
  • Food and Drug Administration. Ceftriaxone (marketed as Rocephin) Information. http://www.fda.gov. Available at http://www.fda.gov/Cder/drug/infopage/ceftriaxone/default.htmAccessed April 2009. 
  • Aiuto LT, Barone SR, Cohen PS, Boxer RA. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Crit Care Med. Jun 1997;25(6):1079-82.  
  • Derkx B, Wittes J, McCloskey R. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clin Infect Dis. Apr 1999;28(4):770-7. 
  • Rivard GE, David M, Farrell C, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr. Apr 1995;126(4):646-52.
  • de Kleijn ED, de Groot R, Hack CE, Mulder PG, Engl W, Moritz B, et al. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med. Jun 2003;31(6):1839-47. 
  • [Best Evidence] Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet. Mar 10 2007;369(9564):836-43.
  • Levin M, Quint PA, Goldstein B, Barton P, Bradley JS, Shemie SD, et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet. Sep 16 2000;356(9234):961-7.
  • Vincent JL, Abraham E, Annane D, Bernard G, Rivers E, Van den Berghe G. Reducing mortality in sepsis: new directions. Crit Care. Dec 2002;6 Suppl 3:S1-18.
  • Day KM, Haub N, Betts H, Inwald DP. Hyperglycemia is associated with morbidity in critically ill children with meningococcal sepsis. Pediatr Crit Care Med. Nov 2008;9(6):636-40. 
  • Herrera R, Hobar PC, Ginsburg CM. Surgical intervention for the complications of meningococcal-induced purpura fulminans. Pediatr Infect Dis J. Aug 1994;13(8):734-7. 
  • Besner GE, Klamar JE. Integra Artificial Skin as a useful adjunct in the treatment of purpura fulminans. J Burn Care Rehabil. Jul-Aug 1998;19(4):324-9. 
  • Faibis S, Widmer R, Sapir S, Peretz B, Shapira J. Meningococcal septicaemia and dental complications: a literature review and two case reports. Int J Paediatr Dent. May 2005;15(3):213-9. 
  • Aaberge IS, Oster P, Helland OS, Kristoffersen AC, Ypma E, Høiby EA, et al. Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic. Clin Diagn Lab Immunol. May 2005;12(5):599-605.
  • Bethell D, Pollard AJ. Meningococcal vaccines. Expert Rev Vaccines. Jun 2002;1(1):75-84.
  • Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J. Dec 2004;23(12 Suppl):S274-9.
  • [Guideline] Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep. Oct 14 2011;60(40):1391-2. 
  • FDA News Release. FDA approves the first vaccine to prevent meningococcal disease in infants and toddlers. April 22, 2011. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm252392.htm. Accessed April 27, 2011. 
  • Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep. Oct 20 2006;55(41):1120-4. 
  • [Guideline] Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. Jan 28 2011;60(3):72-6. 
  • Fraser A, Gafter-Gvili A, Paul M, Leibovici L. Prophylactic use of antibiotics for prevention of meningococcal infections: systematic review and meta-analysis of randomised trials. Eur J Clin Microbiol Infect Dis. Mar 2005;24(3):172-81. 
  • Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease--Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. Aug 5 2011;60(30):1018-9. 
  • Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. Mar 12 2010;59(9):273.
  • Haemophilus influenzae type b (Hib) and meningococcal serogroup C (MenC) vaccines for children - Factsheet.http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_106052. Accessed 8/7/2011. 
  • Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. Jan 28 2011;60(3):72-6. 
  • Endler G, Marculescu R, Starkl P, Binder A, Geishofer G, Müller M, et al. Polymorphisms in the interleukin-1 gene cluster in children and young adults with systemic meningococcemia. Clin Chem. Mar 2006;52(3):511-4.